Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June:

William Blair 41^st Annual Growth Stock Conference (Virtual) on Thursday, June 3, 2021 at 1:00 pm (EDT)
BioPharma Sustainability Roundtable’s CEO Investor Forum on Monday, June 7, 2021 at 1:35 pm (EDT)
Goldman Sachs 42^nd Annual Global Healthcare Conference (Virtual) on Tuesday, June 8, 2021 at 8:00 am (EDT)
Guggenheim’s “Biopharma’s Next Decade: Views from the Top on Global Strategy and Innovation” Series on Monday, June 28, 2021 at 11:00 am (EDT)

The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Contacts

Incyte
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com

Industry:

More News From Incyte

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chroni...